FTY720 administration caused accumulation of stem-like tumor-specific CD8+ T cells in TDLNs and reduced the numbers of more differentiated TCF1-TIM3+PD1+ cells in the tumor (Fig. 3g). The gene discussed is CD8A; the disease is neoplasm.